A total of 14 patients were included in the study as TLD-MTX and compared with the 37 CRIM-positive patients who received ERT monotherapy. promise in inducing immune tolerance to ERT, leading to improved overall Araloside V survival rates. The implementation of immunomodulation concurrent with ERT administration has also resulted in a decreased occurrence of IgG antibody development compared with cases treated solely with ERT. By incorporating the knowledge gained from current approaches and analysing the outcomes of immune tolerance induction (ITI) modalities from clinical and preclinical trials have exhibited significant improvement in the efficacy of ERT. In this comprehensive review, the progress in ITI modalities is usually assessed, drawing insights from both clinical and preclinical trials. The focus is usually on evaluating the advancements in ITI within the context of IEM, specifically addressing LSDs managed through ERT. == Key Points == == Introduction == Enzyme replacement therapy (ERT) is the primary treatment for various inborn errors of the metabolism, including lysosomal storage disorders (LSD), and has been used in other inborn errors of metabolism including phenylketonuria (enzyme substitution therapy) and hypophosphatasia (enzyme substitution therapy) recently (Table1). Recombinant enzymes, derived from human fibroblasts, animal cell lines, or herb cells, are used for ERT [1]. == Table 1. == Inborn errors of metabolism managed with enzyme replacement therapy IVintravenous,ICVintracerebroventricular,IEMinborn errors of metabolism,SCsubcutaneous It is crucial to acknowledge that not all patients who undergo ERT will experience immune responses, which can be influenced by factors such as properties of the replacement protein (immunogenicity, particle aggregation, impurities, dose, route of administration, treatment frequency, and structural similarities to antigens), and host-related issues (residual mutant protein, genetic background). This review aims to overview a comprehensive Rabbit polyclonal to DARPP-32.DARPP-32 a member of the protein phosphatase inhibitor 1 family.A dopamine-and cyclic AMP-regulated neuronal phosphoprotein. examination of contemporary approaches in treating patients receiving ERT, delving into the most recent insights regarding immune responses and their effective Araloside V management. Additionally, it explores the prospective implications for gene replacement therapies in the future treatment landscape. A comprehensive systematic review encompassing publications on inborn errors of metabolism, including infantile onset Pompe disease (IOPD), Pompe disease, glycogen storage disease type 2, immune tolerance induction, immune modulation, immune response, anti-drug antibodies, enzyme Araloside V replacement therapy, lysosomal storage diseases, Fabry disease, Gaucher disease, acid sphingomyelinase deficiency, Wolman disease, mucopolysaccharidosis, phenylketonuria, and hypophosphatasia, was conducted to search the immune tolerance induction (ITI). Case reports, guidelines, meta-analyses, clinical trials, randomised controlled trials, reviews, systematic reviews, and multicentre studies were meticulously selected through the PubMed bibliographic database and thoroughly examined. == The Mechanism of the Immune Response to Enzyme Replacement Therapy == ERT administration may induce an immune response in individuals prior enzyme exposure due to the introduction of a structurally different protein, promoting immunogenicity. Key humoral mechanisms involve antigen-presenting cells (APCs) presenting ERT peptides to helper T cells, triggering B cell activation and leading to the production of antibodies, including short-lived IgM and long-lived IgG [2,3]. The immune system can trigger hypersensitive reactions, such as infusion-associated reactions (IAR), to antigens. Another significant concern is the development of anti-drug antibodies (ADA) in response to enzyme therapy. The presence of residual endogenous enzymes, referred to as cross-reactive immunologic material (CRIM), can impact a patients likelihood of antibody generation against the therapeutic protein. CRIM status is extensively discussed in infantile onset Pompe Disease (IOPD) [4]. Although it has been suggested that CRIM-positive patients with residual enzyme activity have lower antibody titres and respond better to ERT, while CRIM-negative patients with Araloside V severe mutations tend to have high and persistent antibody titres, leading to poor treatment outcomes [4,5], Desai et al. reported there were no differences in the antibody titres between CRIM-negative and positive IOPD patients. Some CRIM-positive IOPD patients develop high and persistent antibody titres (HSAT; 51,200) or sustained intermediate titres (SIT; 12,800 and < 51,200), mirroring the pattern observed in CRIM-negative patients. Within the CRIM-positive IOPD cohort, 32% (12 out of 37) showed the emergence of HSAT/SIT, potentially limiting the response to ERT and impacting clinical outcomes [6]. Notably, it should be emphasised that this magnitude of antibody titres, irrespective of the patient group, did not show significant differences, and, consequently, both groups might experience impediments to the effectiveness of the therapeutic intervention. == Anti-drug Antibodies in Patients Receiving ERT == There are primarily two major issues related to ADAs. The first issue is usually whether the presence of ADAs will give rise to any IARs, and the second concern is usually whether the presence of ADAs will lead to a reduced treatment effect, or negatively impact the patients therapy outcome. The occurrence of IARs.